Selected article for: "early stage and etiologic agent"
Author: Liang, Bo; Yuan, Xudong; Wei, Gang; Wang, Wei; Zhang, Ming; Peng, Haizhou; Javer, Amin; Mendenhall, Michelle; Julander, Justin; Huang, Sammi; Michail, Hany; Lu, Yong; Zhu, Qi; Baldwin, John
Title: In-Vivo Toxicity Studies and In-Vitro Inactivation of SARS-CoV-2 by Povidone-iodine In-situ Gel Forming Formulations
  • Cord-id: tyuoyqtb
  • Document date: 2020_5_20
    • ID: tyuoyqtb
    Snippet: To curb the spread of SARS-CoV-2, the etiologic agent of the COVID-19 pandemic, we characterize the virucidal activity of long-acting Povidone Iodine (PVP-I) compositions developed using an in-situ gel forming technology. The PVP-I gel forming nasal spray (IVIEW-1503) and PVP-I gel forming ophthalmic eye drop (IVIEW-1201) rapidly inactivated SARS-CoV-2, inhibiting the viral infection of VERO76 cells. No toxicity was observed for the PVP-I formulations. Significant inactivation was noted with pre
    Document: To curb the spread of SARS-CoV-2, the etiologic agent of the COVID-19 pandemic, we characterize the virucidal activity of long-acting Povidone Iodine (PVP-I) compositions developed using an in-situ gel forming technology. The PVP-I gel forming nasal spray (IVIEW-1503) and PVP-I gel forming ophthalmic eye drop (IVIEW-1201) rapidly inactivated SARS-CoV-2, inhibiting the viral infection of VERO76 cells. No toxicity was observed for the PVP-I formulations. Significant inactivation was noted with preincubation of the virus with these PVP-I formulations at the lowest concentrations tested. It has been demonstrated that both PVP-I formulations can inactivate SARS-CoV-2 virus efficiently in both a dose-dependent and a time-dependent manner. These results suggest IVIEW-1503 and IVIEW-1201 could be potential agents to reduce or prevent the transmission of the virus through the nasal cavity and the eye, respectively. Further studies are needed to clinically evaluate these formulations in early-stage COVID-19 patients.

    Search related documents:
    Co phrase search for related documents
    • absence presence and local effect: 1
    • absence presence and log reduction: 1
    • absence presence and long duration: 1, 2
    • absence presence and lung weight: 1, 2
    • absence presence and lung weight weight: 1
    • acute sars cov respiratory syndrome coronavirus and adenoviral conjunctivitis: 1
    • acute sars cov respiratory syndrome coronavirus and local effect: 1, 2, 3, 4, 5, 6
    • acute sars cov respiratory syndrome coronavirus and log reduction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and log reduction value: 1, 2
    • acute sars cov respiratory syndrome coronavirus and long duration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute sars cov respiratory syndrome coronavirus and lung thyroid: 1, 2, 3, 4
    • acute sars cov respiratory syndrome coronavirus and lung weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • adenovirus polyomavirus and log reduction: 1
    • log reduction and lrv log reduction value: 1
    • log reduction value and lrv log reduction value: 1